A phase II trial which administered a high dose of trastuzumab–emtansine led to a partial response in 44% of patients with HER2 mutant NSCLC [99]; however, larger randomized studies are needed to demonstrate the true potential of these promising agents. Here, ERBB2 is linked to non-small cell lung carcinoma.